Colistin, used as a last-resort drug, has a narrow therapeutic range that justifies therapeutic drug monitoring. Few data are available in the literature regarding the in vivo unbound fraction of colistin. The objectives of this study were to develop a method to isolate unbound colistin in clinical samples by ultrafiltration and to quantify it. The association between unbound colistin and biological parameters (total protein, albumin, alpha-1-acid glycoprotein and creatinine) was investigated. The measured ranges were 0.036-7.160 mg/L for colistin A and 0.064-9.630 mg/L for colistin B. The process of isolation and determination of unbound colistin was applied to clinical samples ( n = 30) within 40 min and no non-specific binding was observed during the ultracentrifugation step. The median unbound fractions of colistin measured were 34.3% (12.8-51.0%) and 53.4% (27.0-77.8%) for colistin A and B, respectively. High interindividual biological variation of binding was observed for colistin A and B that was not explained by the biochemical parameters studied. The method developed could be useful to improve outcomes for patients.
Introduction
Colistin is mainly used as a last-resort antibiotic in patients with cystic fibrosis [1, 2] and critically ill patients [3, 4] . These populations have altered pharmacokinetic characteristics owing to their disease state that results in unpredictable colistin plasma levels. Moreover, colistin has a narrow therapeutic range, causing nephrotoxicity and neurotoxicity [5, 6] . Thus, therapeutic drug monitoring is useful to optimise dosing in these populations. However, this is complicated by the fact that colistin is administrated as an inactive prodrug, colistin methanesulfonate (CMS), which is hydrolysed in vivo to its microbiologically active form. Moreover, there is no method available for assaying unbound colistin in clinical samples. The majority of data on protein binding by colistin were established in spiked plasma samples and were based on an equilibrium dialysis method [7] [8] [9] [10] . The length of time required for this extraction process is not compatible with determination of unbound colistin in clinical samples owing to the in vitro conversion of CMS into colistin. Therefore, we have developed a separation method based on ultrafiltration to measure unbound colistin levels in clinical samples. In order to develop this method, we have considered the important issues of matrix effect and the non-specific binding of colistin to container surfaces. We also tested this new method in clinical samples by using it to measure unbound and total colistin concentrations in plasma of patients receiving intermittent perfusion of CMS sodium. The correlation between unbound and total colistin as well as the potential influence of several biochemical parameters was investigated.
Materials and methods

Chemicals
Colistin sulfate, CMS, polymyxin B [internal standard (IS)], tigecycline 98% high-performance liquid chromatography (HPLC)-grade and trifluoroacetic anhydride were purchased from Sigma-Aldrich (Bornem, Belgium). Acetonitrile (ACN) and formic acid 99% were obtained from Biosolve B.V. (Valkenswaard, The Netherlands) and were all mass spectrometry (MS)-grade. Ultrapure water was obtained by means of a Milli-Q ® water purification system (Millipore, Brussels, Belgium).
All tubes employed were polypropylene to avoid drug adsorption. Polypropylene vials for liquid chromatography-tandem mass spectrometry (LC-MS/MS) were purchased from Agilent Technologies (Diegem, Belgium). 
High-performance liquid chromatography (HPLC) and mass spectrometry (MS)
Chromatographic separation was carried out using an Agilent 1260 Infinity HPLC System (Agilent Technologies) equipped with a binary pump and an autosampler thermostatically controlled at 15 °C. MS/MS detection was performed using an Agilent 6490 Triple Quad LC-MS/MS System with a Jet Stream electrospray ionisation source (Agilent Technologies).
Biochemical parameters
Assays for total protein, albumin, alpha-1-acid glycoprotein ( α 1 AGp) and creatinine were performed on a Modular Analytics P800 instrument (Roche Diagnostics GmbH, Mannheim, Germany) with Roche Diagnostics kits (TP, ALB plus, α1-acid glycoprotein and CREA).
Clinical samples
Samples were collected from 30 patients infected with multidrug-resistant Gram-negative bacteria and treated with intravenous infusion of CMS (Colistineb ® ; Teva Pharma, Antwerp, Belgium). The regimen was a loading dose of 300 mg colistin base activity (CBA) [ca. 9 million International Units (mIU)] followed by 330 mg CBA (ca. 5 MIU) every 12 h. Characteristics of the 30 patients are detailed in Table 1 . Blood samples were collected in heparinised tubes before the next dose of colistin, were transported on ice and were centrifuged immediately. The supernatants were stored at -80 °C until analysis. Biochemical parameters were measured on the leftover volume of samples. The study was approved by the Ethics Committee of Hôpital Erasme (Brussels, Belgium).
Total colistin assay
The protocol was based on the work published by Jansson et al. [11] with some modifications. A description of the method and the validation process are presented in the Supplementary material. The main modifications were the use of a water/ACN gradient for the mobile phase, a precipitation step, and recovery of the residue obtained after evaporation at room temperature without acidic conditions. Maintenance of a neutral pH during the whole process inhibited the in vitro conversion of CMS into colistin.
Unbound colistin assay
Unbound colistin was separated by ultrafiltration using a 30-kDa Centrifree ® device (number 4104; Merck Millipore, Overijse, Belgium). The assay of unbound concentrations was set up as follows.
2.6.1. Method development 2.6.1.1. Matrix effect. A volume of 1 mL of colistin-free plasma from six different patients not treated with colistin was ultrafiltrated [35 min, room temperature (RT), 40 0 0 rpm, fixed angle of 45 °] to obtain 200 μL of ultrafiltrate. This was spiked at two concentrations (1 mg/L and 10 mg/L of total colistin base A + B) and was added to 100 μL of a colistin-free plasma pool and 50 μL of IS. Proteins were precipitated with 1.2 mL of ACN and were pelleted by centrifugation (10 min, 4 °C, 150 0 0 rpm). Then, 1.2 mL of supernatant was recovered and was evaporated under nitrogen at RT. The residue was reconstituted with 100 μL of 95/5 (v/v) ultrapure water/ACN, was vortex-mixed and was centrifuged (10 min, 4 °C, 150 0 0 rpm). The supernatant was transferred into a vial and 5 μL was injected into the LC-MS/MS system. The measured colistin/IS area ratio was compared with that obtained with the extraction protocol of calibration standards (200 μL of plasma treated with 800 μL of ACN; see Supplementary material). The (aqueous phase/ACN) ratio was the same in the two assays.
Non-specific binding.
Tigecycline was used as IS solely for this experiment. Assessment of colistin losses by non-specific binding to the Centrifree ® device was performed at a concentration of 2.5 mg/L of total colistin base A + B (spiked plasma). Three devices were used for this experiment. The first device (i) served as a control (without pre-treatment). The second (ii) and third (iii) devices were pre-treated with polymyxin B solutions (10 mg/L and 100 mg/L, respectively). Polymyxin B was selected to saturate the sites involved in potential non-specific binding of colistin because it has the same physicochemical characteristics as colistin. After the pre-treatment solution was discarded, 1 mL of sample was introduced into devices (i), (ii) and (iii). Total colistin ( C total ) was determined in the sample compartment before centrifugation. Unbound colistin ( C unbound ) was measured in the ultrafiltrate compartment following centrifugation and after discarding the first ultrafiltrate from devices (ii) and (iii) (3 min of centrifugation, RT, 40 0 0 rpm, fixed angle of 45 °). The results were expressed in terms of ratio (unbound fraction) to normalise the results. The aim of these three precautions was to avoid variability in the results between the two conditions (with and without pretreatment) caused by a dilution of the spiked plasma by trapped pre-treatment solution in devices (ii) and (iii). The ratios were compared between the three conditions.
Determination of unbound colistin in plasma samples
A total of 0.8-1 mL of plasma was introduced into the Centrifree ® device. A 35-min centrifugation step (RT, 40 0 0 rpm, fixed angle of 45 °) was then performed. Next, 200 μL of ultrafiltrate was transferred to an Eppendorf tube containing 100 μL of a colistin-free plasma pool and then 50 μL of IS and 1.2 mL of ACN were added. The mix was centrifuged (10 min, 4 °C, 150 0 0 rpm) and then 1.2 mL of supernatant was recovered and evaporated under nitrogen at RT. The residue was reconstituted with 100 μL of 95/5 (v/v) ultrapure water/ACN, was vortex-mixed and was centrifuged (10 min, 4 °C, 150 0 0 rpm). The supernatant was transferred to a vial and 5 μL was injected into the LC-MS/MS system. Measurement of colistin in the ultrafiltrates provided the C unbound of both colistin A and colistin B.
The repeatability of this protocol was assessed in plasma spiked at two concentrations (1 mg/L and 5 mg/L of total colistin base A + B) in triplicate.
Statistical analysis
The results were analysed using Analyse-it v.3.80 (Analyse-it Software, Leeds, UK). The Shapiro-Wilk normality test was used to assess the distribution of continuous variables. Differences between paired groups were evaluated by the paired t -test (Gaussian distribution) or the Wilcoxon signed-rank-sum test (non-Gaussian distribution). The correlations were estimated using the Pearson ( r ; Gaussian distribution) or Spearman ( r s ; non-Gaussian distribution) coefficient. A P -value of < 0.05 was considered statistically significant. Parametric results are expressed as mean and range and nonparametric results as median and range.
Results
Total colistin assay
The results of the validation are presented in the Supplementary material. The linearity ranges were 0.036-7.160 mg/L for colistin A and 0.064-9.630 mg/L for colistin B. The coefficient of variation of intermediate precision was < 11%. 
Non-specific binding.
Losses of colistin in the Centrifree ® device were evaluated by comparing the colistin unbound fraction in spiked plasma obtained from a device without pre-treatment and from two devices in which their potential binding sites were neutralised by a solution of 10 mg/L or 100 mg/L polymyxin B. The unbound fractions were 20% (17-20%) for colistin A and 37% (35-38%) for colistin B in the three conditions, indicating that there was no significant binding of colistin to the device.
Repeatability of the determination of unbound colistin
The repeatability of the determination of unbound colistin was evaluated in spiked samples. The imprecision of C unbound was 12% for colistin A and 7% for colistin B for a total concentration of 1 mg/L, and 4% for colistin A and 3% for colistin B for a total concentration of 5 mg/L.
Determination of the unbound fraction of colistin in clinical samples
The evaluated protocol was then used to determine unbound colistin concentrations in 30 clinical samples in which the range of total colistin was 0.36-4.98 mg/L for colistin A and 0.20-2.05 mg/L for colistin B. The median unbound colistin concentration was 0.44 mg/L (0.05-2.19 mg/L) for colistin A and 0.21 mg/L (0.08-1.13 mg/L) for colistin B, corresponding to unbound fractions of 34.3% (12.8-51.0%) and 53.4% (27.0-77.8%) for colistin A and B, respectively. A significant correlation was observed between the total and unbound concentrations both for colistin A and B (colistin A, r s = 0.95; colistin B, r s = 0.81) ( Fig. 1 ) but not between unbound fractions and biological parameters such as total protein, albumin, α 1 AGp or creatinine (colistin A, r or r s < 0.20; colistin B, r or r s < 0.30). Likewise, no correlation was observed between the unbound fraction and C total of colistin (colistin A, r s = 0.16; colistin B, r s = -0.17) ( Fig. 2 ) .
Discussion
We have developed a simple LC-MS/MS method for colistin quantification before ( C total ) and after ( C unbound ) ultrafiltration that allows the determination of the unbound colistin fraction. In comparison with other published methods, this protocol displays several advantages. First, the isolation step for unbound colistin, requiring 800 μL of sample only, was relatively short (ca. 40 min), preventing the conversion of CMS into colistin. Second, the analytical range validated fulfils clinical expectations [3, 4, 9] . Third, the extraction procedure with ACN was less expensive, faster and easier than procedures that use a solid phase extraction (SPE) cartridge [7, [12] [13] [14] . Fourth, the precipitation step and reconstitution of the dry residue without acidic conditions prevented the conversion of CMS into colistin [14, 15] .
For development of the unbound colistin assay, the first major point to investigate was the ability of the method to quantify colistin in a mix of ultrafiltrate and plasma because the initial protocol was developed for plasma. The recoveries in the two matrices were in close agreement. Therefore, the matrix effect was considered to be non-significant and plasma standards were used for the calibration curves, and the analytical performance of the total colistin assay (see the Supplementary material) was applicable for the unbound colistin assay.
The second major point to investigate was the non-specific binding of colistin to the Centrifree ® device. The results obtained showed that the device was reliable for the quantification of unbound colistin concentration in clinical samples without pretreatment of the device.
A total of 30 clinical samples were analysed and demonstrated substantial interindividual variation in the unbound colistin fraction. Mean values of the unbound fraction (34.3% for colistin A and 53.4% for colistin B) were comparable with those reported in the literature [7] [8] [9] 12, 16, 17] for spiked samples after equilibrium dialysis or ultrafiltration (colistin A, 30-42%; colistin B, 43-60%) but higher than those observed in an in vivo microdialysis study (2.8-14.1% [10] ). The low unbound colistin fraction observed in that study may be explained by non-specific binding of colistin, which is likely to occur in a dialysis device. Furthermore, the study was performed on healthy volunteers receiving a single subtherapeutic dose of CMS, possibly associated with higher protein binding.
A good linear relationship between unbound and total colistin in clinical samples suggests that no saturation of protein binding occurs at therapeutic concentrations. Such a correlation was observed in the study of Dudhani et al. [8] but not with the protocol of Cheah et al. where the study was performed in mice [17] . This difference might explain the absence of a relationship between unbound and total colistin, as a high level of protein binding of colistin ( > 90%) was observed in mice. Therefore, it might be difficult to highlight a concentration-dependent relationship at therapeutic levels because the unbound colistin values were very low.
In the current study, high interindividual variation in unbound colistin concentrations was observed. The differences could not be explained by albumin or α 1 AGp levels (potential colistin binding proteins) nor by serum creatinine level (an important covariate in the population pharmacokinetic/pharmacodynamic model of Garonzik et al. [4] ). Nation et al. observed the same variability in their study (unbound fraction of colistin A + B, 49 ± 11%) [16] . Other individual factors might explain this variability, such as co-administration of other drugs competing for protein binding sites or patient co-morbidities. These factors need to be further explored. The current data suggest that adjustment of the drug dosage on the basis of total concentrations (as is current practice) might not be as appropriate as expected and that monitoring of unbound concentrations could be more informative. A new challenge would thus be to establish targets for unbound colistin that could improve the outcome of patients.
Supplementary Table S1
Criteria of analytical performance (trueness, precision and linearity) obtained for plasma total colistin base A and B measurement. Validation standards were analysed at six different concentrations. Calibration curves were built using a 1/X weighted quadratic regression CV, coefficient of variation; CI, confidence interval. a Level not acceptable (total error was above the accuracy limit).
